BioArctic AB
Swedish research-based biopharma focused on discovery and development of disease-modifying therapies and diagnostics for neurodegenerative diseases. Core activities include discovery and development of monoclonal antibodies against aggregated protein species, platform approaches for active transport of biologics across the blood–brain barrier, biomarker and diagnostic assay development for CSF and blood, clinical development across Phase 1–3, and partnering/licensing for global development and commercialization. The company has collaborated with partners on clinical-stage antibody therapeutics and formulation strategies, including partner-led regulatory submissions for subcutaneous maintenance dosing.
Industries
Nr. of Employees
medium (51-250)
BioArctic AB
Warfvinges väg 35, SE-112 51 Stockholm, Sweden
Patents
Method for treatment of traumatic brain injury targeting aggregated peptides
US-11327080-B2
View DetailsAntibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders
US-9315569-B2
View DetailsProtofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other α-synucleinopathies
US-9084832-B2
View Details
Method for treatment of traumatic brain injury targeting aggregated peptides
US-11327080-B2
View DetailsAntibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders
US-9315569-B2
View DetailsProtofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other α-synucleinopathies
US-9084832-B2
View DetailsProducts
Anti‑amyloid‑beta monoclonal antibody for early Alzheimer’s disease
A monoclonal antibody selectively targeting aggregated amyloid‑beta species developed through clinical studies (Phase 2b and Phase 3) as a disease‑modifying therapy for early Alzheimer's disease where regulatory approval has been obtained by partners.
Antibody program targeting aggregated alpha‑synuclein
Monoclonal antibody program designed to bind aggregated pathological alpha‑synuclein with the objective of modifying disease progression in Parkinson’s disease and other synucleinopathies; progressed into early clinical studies.
Biodegradable implant delivering growth factor for spinal cord injury (combination product)
A combination device–drug product consisting of a biodegradable implant containing a growth factor designed to support nerve fiber guidance and regeneration following severe spinal cord injury; progressed to Phase 1/2 clinical evaluation.
Anti‑amyloid‑beta monoclonal antibody for early Alzheimer’s disease
A monoclonal antibody selectively targeting aggregated amyloid‑beta species developed through clinical studies (Phase 2b and Phase 3) as a disease‑modifying therapy for early Alzheimer's disease where regulatory approval has been obtained by partners.
Antibody program targeting aggregated alpha‑synuclein
Monoclonal antibody program designed to bind aggregated pathological alpha‑synuclein with the objective of modifying disease progression in Parkinson’s disease and other synucleinopathies; progressed into early clinical studies.
Biodegradable implant delivering growth factor for spinal cord injury (combination product)
A combination device–drug product consisting of a biodegradable implant containing a growth factor designed to support nerve fiber guidance and regeneration following severe spinal cord injury; progressed to Phase 1/2 clinical evaluation.
Services
Structuring and executing research evaluation agreements, licensing options, out‑licensing of antibody programs, and co‑commercialization arrangements in defined regions.
Structuring and executing research evaluation agreements, licensing options, out‑licensing of antibody programs, and co‑commercialization arrangements in defined regions.
Expertise Areas
- Antibody therapeutics for neurodegenerative diseases
- Transferrin receptor-mediated blood–brain barrier delivery
- Clinical development and trial management for CNS indications
- Biomarker discovery and diagnostic assay development
Key Technologies
- Monoclonal antibody therapeutics
- Transferrin receptor-mediated BBB transport
- Biodegradable implantable devices for growth factor delivery
- CSF and plasma biomarker assays
News & Updates
Entered a research evaluation agreement to apply a transferrin receptor-based brain delivery approach to a partner’s Alzheimer drug candidate; the partner will evaluate generated data and may exercise a licensing option.
Investor event outlining strategic ambitions to 2030 including pipeline expansion, partnerships, and Nordic commercialization plans.
Global license executed for a pyroglutamate‑amyloid‑beta antibody program including upfront and milestone payments and application of brain delivery technology in one program.
Regulatory approval in Norway to include patients in Phase 1/2 study for spinal cord implant program
Authorization received to include Norwegian patients in an ongoing Phase 1/2 study of a biodegradable implant combined with growth factor for complete spinal cord injury.
Interim Phase 1/2 results did not meet the primary efficacy endpoint (absence of measurable motor evoked potentials), leading to termination of patient inclusion and program stoppage.
Presented clinical and binding‑profile data for antibodies targeting alpha‑synuclein and amyloid‑beta; partner presented real‑world data for a partnered anti‑amyloid therapy.
Entered a research evaluation agreement to apply a transferrin receptor-based brain delivery approach to a partner’s Alzheimer drug candidate; the partner will evaluate generated data and may exercise a licensing option.
Investor event outlining strategic ambitions to 2030 including pipeline expansion, partnerships, and Nordic commercialization plans.
Global license executed for a pyroglutamate‑amyloid‑beta antibody program including upfront and milestone payments and application of brain delivery technology in one program.
Regulatory approval in Norway to include patients in Phase 1/2 study for spinal cord implant program
Authorization received to include Norwegian patients in an ongoing Phase 1/2 study of a biodegradable implant combined with growth factor for complete spinal cord injury.
Interim Phase 1/2 results did not meet the primary efficacy endpoint (absence of measurable motor evoked potentials), leading to termination of patient inclusion and program stoppage.
Presented clinical and binding‑profile data for antibodies targeting alpha‑synuclein and amyloid‑beta; partner presented real‑world data for a partnered anti‑amyloid therapy.